Edition:
United States

Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

25.53USD
13 Jan 2017
Change (% chg)

-- (--)
Prev Close
$25.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
374,057
52-wk High
$41.69
52-wk Low
$22.67

Latest Key Developments (Source: Significant Developments)

Acceleron Pharma reports Q3 financial and operational results
Thursday, 3 Nov 2016 04:05pm EDT 

Acceleron Pharma Inc : Acceleron Pharma Inc qtrly earnings per share $0.55 .Acceleron Pharma reports third quarter 2016 financial and operational results.  Full Article

Acceleron:Habib Dable named president and ceo
Tuesday, 27 Sep 2016 04:01pm EDT 

Acceleron Pharma Inc : Acceleron announces retirement of John Knopf as president and ceo; Habib Dable named as successor . Habib Dable appointed as president and ceo .Acceleron Pharma Inc says Habib Dable will assume ceo role effective December 1, 2016.  Full Article

Acceleron Pharma Q2 loss per share $0.59
Thursday, 4 Aug 2016 07:00am EDT 

Acceleron Pharma Inc : Acceleron Pharma reports second quarter 2016 financial and operational results . Q2 loss per share $0.59 .Q2 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron announces ACE-083 phase 1 results
Friday, 8 Jul 2016 07:00am EDT 

Acceleron Pharma Inc : Announces ACE-083 phase 1 results at 14th International Congress On Neuromuscular Diseases . ACE-083 increased muscle volume of tibialis anterior muscle by 8.9% in healthy volunteers .Acceleron intends to advance ACE-083 into a phase 2 clinical trial in patients with FSHD in second half of 2016..  Full Article

Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels
Friday, 10 Jun 2016 07:00am EDT 

Acceleron Pharma Inc : Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association . Longer term data with investigational drug Luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden . Results showed 51% of patients with lower risk MDS treated with Luspatercept (n=49) achieved increased hemoglobin levels .Results showed 36% of patients achieved a hemoglobin increase of at least 1.5 g/dl in Luspatercept 3-month base study.  Full Article

Acceleron Announces Proposed Public Offering of Common Stock
Monday, 4 Jan 2016 04:58pm EST 

Acceleron Pharma Inc:intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offering.As part of this offering Acceleron intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the number of shares sold.All of the shares in the offering are to be sold by Acceleron.Morgan Stanley, Leerink Partners LLC and UBS Investment Bank are acting as joint book-running managers for the offering.JMP Securities is acting as the lead manager.Acceleron intends to use net proceeds from the offering to conduct clinical trials and associated activities in connection with ACE-083 and Acceleron's other potential therapeutic candidates, including antibodies and proteins from Acceleron's IntelliTrap platform.to further expand Acceleron's research and development efforts, and for general and administrative expenses, potential future development programs, capital expenditures and working capital and other general corporate purposes.  Full Article

Celgene Corporation and Acceleron Pharma Inc announces FDA granted Fast Track Designation to luspatercept for treatment of anemia
Monday, 7 Dec 2015 07:00am EST 

Celgene Corporation and Acceleron Pharma Inc:Announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS).Fast Track program of the FDA is designed to facilitate the development, and expedite the review, of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.  Full Article

Celgene Corporation and Acceleron Pharma Inc announces FDA fast track designation granted to Luspatercept
Monday, 18 May 2015 07:30am EDT 

Celgene Corporation and Acceleron Pharma Inc:Says FDA has granted Fast Track designations to luspatercept for two separate indications; the use of luspatercept for the treatment of patients with transfusion dependent beta-thalassemia and the use of luspatercept for the treatment of patients with non-transfusion dependent beta-thalassemia.Says Celgene and Acceleron are jointly developing luspatercept.  Full Article

Acceleron Pharma plan to initiate a phase 3 program
Thursday, 30 Apr 2015 07:35am EDT 

Acceleron Pharma Inc:Acceleron and collaboration partner Celgene Corporation plan to initiate a phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015.Companies continue to develop sotatercept for patients with chronic kidney disease.  Full Article

Acceleron Pharma appoints Francois Nader as Chairman
Monday, 6 Apr 2015 07:00am EDT 

Acceleron Pharma Inc:Appoints Francois Nader, M.D., M.B.A, as Chairman of its Board of Directors.  Full Article

BRIEF-Acceleron outlines corporate goals and priorities for 2017

* Plan to initiate new luspatercept phase 2 clinical trials in distinct patient segments in MDS and Beta-Thalassemia